Reeves D S, Morris R W, Watts M R, Reeves R E
Curr Med Res Opin. 1980;6(7):481-7. doi: 10.1185/03007998009109473.
A double-blind trial was carried out in 177 patients with acute symptomatic urinary tract infections to assess the efficacy and tolerability of nitrofurantoin plus sulphadiazine at two dosage levels. Patients were allocated, at random, to receive 7-days' treatment with either 50 mg nitrofurantoin plus 150 mg sulphadiazine 3-times daily or 100 mg nitrofurantoin plus 500 mg sulphadiazine 3-times daily, and were followed-up 10 to 14 days later. Only the 73 (41%) patients with significant bacteriuria on entry were included in the analysis of the efficacy results. There were no statistically significant differences between the two treatments either in bacteriological cure rates, which were approximately 90% in both groups, or in the complete or partial resolution of symptoms, recorded in over 90% of patients at the 2-week follow-up visit. The main side-effects recorded were anorexia, nausea, vomiting and/or headache, and were fewer in the group treated with the lower dosage.
对177例急性症状性尿路感染患者进行了一项双盲试验，以评估两种剂量水平的呋喃妥因加磺胺嘧啶的疗效和耐受性。患者被随机分配，接受为期7天的治疗，每日3次，每次服用50毫克呋喃妥因加150毫克磺胺嘧啶，或每日3次，每次服用100毫克呋喃妥因加500毫克磺胺嘧啶，并在10至14天后进行随访。仅将73例（41%）入院时患有显著菌尿的患者纳入疗效结果分析。两种治疗在细菌学治愈率方面无统计学显著差异，两组的细菌学治愈率均约为90%，在2周随访时，超过90%的患者症状完全或部分缓解方面也无差异。记录的主要副作用为厌食、恶心、呕吐和/或头痛，低剂量治疗组的副作用较少。
